CollPlant is a regenerative Medicine Company focused on developing and commercializing tissue repair products, initially for orthobiologics and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant’s proprietary plant based genetic engineering technology.
Our product candidates address indications for diverse fields of tissue repair and are ushering in a new era in regenerative medicine. Our flagship Vergenix line of rhCollagen products include a soft tissue repair matrix for treating tendinopathy, a surgical matrix for spinal fusion and bone trauma and a wound filler to promote a rapid optimal healing of acute and chronic wounds (was granted CE Mark in 2016).
Chief Executive Officer
Yehiel is a seasoned executive in the biomedical field and brings over two decades of management experience in both high-tech and biotech companies. Prior to joining CollPlant, Yehiel served as CEO and co-founder of Regentis Biomaterials Ltd.; Vice-President of Business Development at ProChon BioTech Ltd.; Vice President of Marketing and Business Development at OrthoScan Technologies Ltd.; and Director of Business Development and Business Unit Manager at Kulicke and Soffa Industries, Inc. Yehiel holds a BSc and an MSc degree in Mechanical Engineering from the Technion-Israel Institute of Technology.
Founder and Chief Scientific Officer
Oded is a faculty member of the Hebrew University of Jerusalem and has accumulated extensive experience with plant molecular biology and protein engineering. He has authored more than 160 scientific publications and is the inventor of 46 patents. He received the Outstanding Scientist Polak Award in 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research and the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. In addition to CollPlant, Oded is the scientific founder of nine companies, among them CBD-Technologies/FuturaGene, SP Nano Ltd., Melodea Ltd., Valentis Nanotech. Ltd. and Paulee CleanTec Ltd.
Chief Financial Officer
Eran is a veteran financial executive in the biotech and industrial sectors. Prior to joining CollPlant, Eran served as the Chief Financial Officer of Tefron Ltd., a global industrial company traded on both the Tel Aviv Stock Exchange (TASE:TFRN) and on the OTCBB (OTC:TFRFF) in the U.S. he also served as Chief Financial Officer of Healthcare Technologies Ltd. (NASDAQ:HCTL), Gamida MedEquip and Gamida For Life, a group of companies specializing in the development, manufacturing and marketing of clinical diagnostic test kits worldwide and medical equipment and services to the biotech and high tech industries. Prior to Gamida, Eran served as a senior manager at Ernst & Young. Eran holds a BA in Accounting and Business Administration from the Tel Aviv College of Management and is a Certified Public Accountant.
Vice President of R&D
Nadav is an accomplished R&D manager with specific experience in the bio-surgery products. Prior to joining CollPlant, Nadav served as an Associate Director and manager of an R&D group at Omrix Biopharmaceuticals Ltd., a subsidiary of ETHICON Biosurgery, a Johnson & Johnson company. While at Omrix, Nadav led an international team developing hemostatic combination products and led base business support for production processes and products. Nadav holds a PhD from the Weizmann Institute of Science.
Vice President of Regulatory Affairs and Quality Assurance
Philippe brings over two decades of experience in Regulatory Affairs, Quality Assurance and Clinical Affairs in the international medical device industry. Prior to joining CollPlant, Philippe served for 14 years as Director of RA/QA/CA at InterVascular Datascope (now Maquet-Getinge), a manufacturer of cardiovascular long-term implants. He was also with 3M Medical, as Manager of Regulatory Affairs. Philippe holds a PharmD degree from the University of Pharmacy in Marseille, France.
Chief Operations Officer
Ilana joined CollPlant in 2015, bringing extensive executive experience in managing Operations as well as Research and Development processes in the biotechnology and pharmaceutical industries. Ilana holds a Ph.D from the Tel Aviv University. Prior joining CollPlant Ilana served as COO at BioHarvest, an innovative botanical biotech company. Ilana's previous positions included: 14 years as an R&D and product manager at SERONO-InterPharm Laboratories, VP R&D and Operations at Procognia and Plant Manager at Omrix Biopharmaceuticals Ltd. In these positions, she was responsible for a wide range of operations activities including process development, production, logistics, technical support and packaging. Dr. Belzer gained vast experience in R&D management as well as GMP production of pharmaceutical products, business development projects and led the planning and construction of new production facilities.
Vice President Commercialization
Shomrat brings over two decades of diverse experience in marketing, sales, regulatory and strategy management. Prior to joining CollPlant, Shomrat served as a Senior Director at Protalix Biotherapeutics Inc. (NYSE: PLX), where she oversaw the company’s lead product through its clinical development, FDA approval and commercialization. Prior to that, she held executive positions in BBDO Proximity (C.E.O), BHI, Clal Holdings Insurance. Shomrat holds a M.Sc. and B.Sc. degree in Biology from Tel Aviv University.
Chairman of the Board
Mr. Adi Goldin has been the Interim Chairman of the Board since May 29, 2016 and continues to serve the Company in this role to the present. He brings vast experience in the life science, industrial and hi-tech industries in the areas of investments, business strategy, deal structure and company management. Mr. Goldin served as a vice president at Docor International BV, and played a key role in investing, managing and nurturing technology-driven companies and startups in the information technology, industrial and life science industries. Until 2010, Mr. Goldin was the CEO of Softlib, an information technology company and served as VP of Investments and Analysis at Inventech Venture Capital (TASE: IVTC). Mr. Goldin practiced law in the offices of Israeli, Blustein, Kogan & Co. and was on the faculty of the joint MBA program of Tel Aviv University and Northwestern University's Kellogg School of Management. Mr. Goldin is a member of the Israel Bar Association and holds a BA and MA degree in economics and an LL.B from Tel Aviv University.
Mr. Ira Leiderman is a founder and Managing Partner of Long Trail Advisors LLC, a lifesciences advisory firm and M&A boutique. Mr. Leiderman formed Long Trail after his departure from Ladenburg Thalmann & Co. in New York City where he was co-head of the Healthcare Group. He joined Ladenburg when that firm acquired Punk Ziegel & Company in May 2008. At Punk Ziegel he was Head of Healthcare and sat on the Firm’s management committee. Prior to Punk Ziegel, Ira was at the Palladin Group, an investment management firm where he oversaw investment transactions in public and private life sciences companies. Ira joined Palladin, after leading the healthcare practice at Gerard Klauer Mattison (now part of BMO). Ira currently serves on the Board of MarginSurgical, Inc. and was Chairman of the Board of Apthera Inc. He also serves on the board of Camp Ramah in the Berkshires and several other not-for-profit organizations.
Mr. Rami Armon has served on our board of directors as an external director since October 2011, and is the chairman of our audit, compensation and financial statements committees. Mr. Armon is the chief executive officer and founder of Armon Capital Management Ltd., a company that offers services in the area of private equity, investment services and corporate finance. Previously, Mr. Armon was vice president and chief investment officer of Menora Mivtachim Pension Ltd. Mr. Armon holds a Bachelor's degree from Bar Ilan University, Israel where he studied investments and securities.
David Tsur joined our board of directors in March 2017. Mr. Tsur is the Co-founder of Kamada Ltd and served as its Chief Executive Officer and on its board of directors since Kamada's inception, in 1990 , and until July 2015. Currently he serves as Kamada's Active Deputy Chairman of the Board.
Prior to co-founding Kamada, Mr. Tsur was Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran.
Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem.
Gili Hart is a Biotech executive serving as OPKO Biologic’s General Manager since 2014. Dr. Hart brings extensive experience in managing critical global programs ranging from preclinical work through Phase 3 clinical trials. Dr. Hart has broad experience in global regulatory strategic planning and interactions and partnering deals with large-pharma, public company road shows and financing.
Dr. Hart served as VP of Pre-clinical and Clinical Pharmacology in PROLOR Biotech from 2013-2009 and before that as a Senior Director.
During the period from 2005-2007, Dr. Hart was a Research Fellow in the Immunology Department at the Weizmann Institute of Science in collaboration with Faculty of Immunobiology, Yale University’s School of Medicine. She received her PhD cum laude from the Weizmann Institute and also graduated summa cum laude from the Technion with a Biotechnology Engineering Degree.
Dr. Hart has published numerous papers and patents and in her scientific work, she focused on autoimmunity diseases as well as on B and T cells migration that can directly affect inflammation and immune conditions.
Dr. Havron joined our board of directors in May 2016 bringing with him his extensive experience in the biotechnology sector. Since 2011, Dr. Havron has been serving as an external director at Kamada as well as being a member of their company audit and compensation committees. From 2005, Dr. Havron was the CEO and Director of PROLOR Biotech Inc. (NYSE MKT: PBTH; TASE: PROL) until it was acquired by OPKO Health Inc. in 2013. Dr. Havron also served as the Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. From 1987 to 1999, Dr. Havron was the Vice President Manufacturing and Process Development at BioTechnology General Ltd. which is currently a subsidiary of Ferring Pharmaceuticals. In 1980 he joined the founding team of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) and was Director of Research and Development until 1987. Dr. Havron holds a PhD in Bio-Organic Chemistry from the Weizmann Institute of Science and served as Research Fellow at Harvard Medical School between 1978-1980.
Mr. Xiaojin QIAN is the Managing Director of Flon (China) Medical Material Co., Ltd and a Board member of Jiangsu Traumark Holdings Group Co., Ltd and Trauwin Pty Ltd.
Mr. Xiaojin QIAN graduated from Simon Fraser University with Master of Business Administration in 2009. Until March 2013, he serves as Vice President in Trauson Holding Co., Limited, a leading manufacturer of orthopedic products in China. Previously, Mr. Xiaojin QIAN was Director of Public Relations, Secretary of the Board, and Secretary of President in Trauson. He is experienced in maintaining relationships with public and other companies and is also doing well in carrying out operational management duties.
Unit Of Biochemistry, Technion Nobel Laureate in Chemistry 2004
Avram Hershko was born in 1937 in Hungary and emigrated with his family to Israel in 1950. He gained his MD (1965) and PhD (1969) from the Hebrew University- Hadassah Medical School of Jerusalem. After a post-doctoral fellowship at the University of California of San Francisco (1969-72), he joined the faculty of the Haifa Technion becoming professor in 1980. He is now Distinguished Professor in the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion. His main research interests concern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study. Hershko and his colleagues showed that cellular proteins are degraded by a highly selective system. This system tags proteins for destruction by linkage a protein called ubiquitin, which had previously been identified in many tissues, as the name suggests, but whose function was previously unknown. Subsequent work in Hershko's and many other laboratories has shown that the ubiquitin system has a vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction and DNA repair. Abnormalities in the ubiquitin system result in diseases such as certain types of cancer. The full range of functions of the ubiquitin system in health and disease has still to be elucidated. Hershko was awarded the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanover and his colleague Irwin Rose. His many other honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), The Alfred P. Sloan Prize of the General Motors Cancer Research Foundation (2000), the Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001). Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the US Academy of Sciences (2003).
Harvard School of Dental Medicine
Vicki Rosen is currently Professor and Chair, Department of Developmental Biology, Harvard University School of Dental Medicine where her research is focused on the formation, maintenance and regeneration musculoskeletal tissues. Prior to joining the faculty of medicine at Harvard, she was Director of Tissue Growth and Repair at Genetics Institute, Inc., where she was part of the research team that identified the bone morphogenetic protein (BMP) genes in 1988. She has 30 US patents and 3 US FDA approved products in the area of tissue regeneration. She received an honorary degree from Harvard University in 2001, was co-recipient of the ORS Kappa Delta Award for outstanding orthopedic research in 2008, and the ORS Marshall Urist Award for excellence in tissue engineering in 2009.
National University of Ireland, Galway
Abhay Pandit is the Director of a Science Foundation Ireland funded Strategic Research Cluster “Network of Excellence for Functional Biomaterials” (NFB) at the National University of Ireland, Galway. Prof Pandit research programme hosts several patented technology platforms associated with the development of implantable materials for clinical applications. Functionality to these forms is achieved through custom chemistries which facilitate the attachment of surface tethered moieties or encapsulated therapeutic factors including drugs, genes and other active agents. His research is currently funded by Science Foundation Ireland, Enterprise Ireland, Health Research Board, Dystrophic Epidermal Bullosa Research Association, 7th EU Framework, European Molecular Biology Organization and AO Foundation amongst others. He has generated research contracts from industry and government funding agencies totaling €17,229,006.40 in the last 7 years. He is the author of 2 patents with 9 other patent applications are pending. He has published 75 papers in high-impact factor publications including Trends in Biotechnology, Small, Biomaterials and Tissue Engineering and has authored 267 papers at both national and international conferences in the past eight years.
Abhay Pandit is a member of the editorial board of 8 journals including Biomaterials, European Cells and Materials and The Journal of Materials Science: Materials in Medicine. He also acts as a Referee for 42 journals in cognate areas. He is a Grant Panelist for 5 funding agencies including The Leverhulme Trust, The Academy of Finland’s Panel in Biomedical Engineering, and The Irish-US Fulbright Commission. He is a Grant Reviewer for 16 funding agencies including the 7th EU Framework, the UK’s Medical Research Council, the AO Foundation, the Welcome Trust, the Agency for Science, Technology and Research’s (A*STAR) Biomedical Research Council (BMRC), the Engineering and Physical Sciences Research Council (EPSRC), The Biotechnology and Biological Sciences Research Council (BBSRC), The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) Research Grants, the Swiss National Science Foundation and the Dutch Burns Foundation. Prof. Pandit hosted the Tissue Engineering Regenerative Medicine International Society Conference – EU Meeting in 2010 and will host The European Society for Biomaterials Conference in 2011 – one of the few groups to host these prestigious conferences in consecutive years.
In addition for his contribution to the society at large he was recently elected on the board of TERMISEU Council. Abhay sees his role in the council as an active contributor to the strategic direction of TERMIS-EU. Specifically he sees a role in adding high value to the annual conference and developing a support base for young and upcoming researchers in the Society.
MD, Hospital for Special Surgery
Dr. Lane’s research interests include collagen metabolism, cartilage preservation and transplantation, bone regeneration and connective tissue injury and repair. Formal training included a chemistry undergraduate degree, graduating Magna Cum Laude from Columbia University and M.D. from Harvard University. In addition to clinical professorship posts, Dr. Lane has held numerous positions for on-going research in orthopaedics with the National Institute of Health and the American Academy of Orthopaedic Surgeons. He is presently Professor of Orthopaedic Surgery and Assistant Dean, Medical Students at Weill Cornell Medical College, New York. He is an Attending, Orthopaedic Surgery at Hospital for Special Surgery, New York. He has served as Chief of Bone Tumors at Memorial Sloan-Kettering Cancer Center, New York and Chairman of Orthopaedics at UCLA.
Dr. Lane has served as Chairman to many professional society functions and committees. His influence in orthopaedic research is evidenced by hundreds of publications, book chapters and scientific articles. In addition, Dr. Lane has contributed to orthopaedic knowledge as a frequent visiting professor and corporate consultant domestically and internationally.
MD MCh (Orth)
Consultant Orthopaedic, Shoulder and Elbow Surgeon. Professor and Chair of the Orthopaedic Surgery Research and Learning Centre - at Brunel University, West London. Director of the Reading Shoulder Unit, an international centre of excellence for shoulder and elbow surgery, Reading, United Kingdom. The unit is recognised worldwide, as a clinical, academic and research centre. Ofer Levy studied medicine at the Hebrew University and Hadassah School of Medicine, Jerusalem and his orthopaedic surgical training at Sheba Medical Centre, Israel. He is assistant editor, Journal of Shoulder and Elbow Surgery, On the Editorial board of the International Journal of Shoulder Surgery. Special External Examiner, the national university of Ireland and the Royal College of Surgeons in Ireland. Awarded UK national bronze clinical excellence award in 2006. Awarded the Kessel best research award of the British Elbow and Shoulder Society 2010. Member of the British and Israeli Orthopaedic associations. He is a founder member of the Israeli Shoulder and Elbow Society, a member of the European Society of Shoulder and Elbow Surgery and the British Elbow and Shoulder Society (BESS) and corresponding member of the American Shoulder and Elbow Society (ASES) - for outstanding contribution in the field. Organises international courses on shoulder surgery, for arthroscopic surgery and shoulder arthroplasty. He has published over 400 scientific papers and presentations, written chapters to books on shoulder surgery and invited to lecture worldwide.